Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer

Michael Chuong; Hayman TJ, Patel M, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE

Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer

Michael Chuong
, Hayman TJ, Patel M, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Gastrointestinal cancer research : GCR
Volume	4
State	Published - 2011

Disciplines

Medicine and Health Sciences
Oncology

Cite this

Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. / Chuong, Michael; Choi J, Shridhar R, Hoffe SE, Hayman TJ, Patel M, Russell MS, Malafa MP, Hodul PJ, Springett GM,.
In: Gastrointestinal cancer research : GCR, Vol. 4, 2011.

Research output: Contribution to journal › Article › peer-review

@article{7333a13d06f647e5a4c3dea110157dca,

title = "Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer",

author = "Michael Chuong and \{Choi J, Shridhar R, Hoffe SE\}, \{Hayman TJ, Patel M, Russell MS, Malafa MP, Hodul PJ, Springett GM,\}",

note = "BACKGROUND: Facilitation of margin-negative resection is the goal of neoadjuvant therapy regimens used in the treatment of borderline-resectable pancreatic cancer patients. Multiple treatment approaches have shown efficacy in this setting, including neoadjuvant GTX (gemcitabine [Gemzar], docetaxel [Taxotere], and capecitabine [Xeloda]) and radiotherapy (RT).",

year = "2011",

language = "American English",

volume = "4",

journal = "Gastrointestinal cancer research : GCR",

}

TY - JOUR

T1 - Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer

AU - Chuong, Michael

AU - Choi J, Shridhar R, Hoffe SE, Hayman TJ, Patel M, Russell MS, Malafa MP, Hodul PJ, Springett GM,

N1 - BACKGROUND: Facilitation of margin-negative resection is the goal of neoadjuvant therapy regimens used in the treatment of borderline-resectable pancreatic cancer patients. Multiple treatment approaches have shown efficacy in this setting, including neoadjuvant GTX (gemcitabine [Gemzar], docetaxel [Taxotere], and capecitabine [Xeloda]) and radiotherapy (RT).

PY - 2011

Y1 - 2011

UR - https://www.ncbi.nlm.nih.gov/pubmed/22368736

M3 - Article

VL - 4

JO - Gastrointestinal cancer research : GCR

JF - Gastrointestinal cancer research : GCR

ER -

Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer

Disciplines

Other files and links

Cite this